Brief: Oryzon Announces Submission Of Phase Iii Protocol To FDA To Initiate Portico-2 Trial
23/06/2025 13:04
June 23 (Reuters) - Oryzon Genomics SA ORY.MC: ORYZON ANNOUNCES SUBMISSION OF PHASE III PROTOCOL TO FDA TO INITIATE PORTICO-2 TRIAL OF VAFIDEMSTAT IN BORDERLINE PERSONALITY DISORDER (BPD) PATIENTS ORYZON GENOMICS SA - PROTOCOL FINALIZED FOLLOWING FDA GUIDANCE AND INPUT FROM PSYCHIATRY EXPERTS Source text: ID:nGNX7lnPjC Further company coverage: ORY.MC ((Reuters.Briefs@thomsonreuters.com;))
Recent news on ORYZON Genomics SA
See all newsBrief: Oryzon Gets New Patent Grants For Vafidemstat In Four Countries
Brief: Oryzon Gets EMA Approval To Start Phase II Study Of Vafidemstat For PMS Treatment
Spanish stocks - Factors to watch on Aug 31
Brief: Oryzon Gets U.S. Patent Allowance For Iadademstat And Gilteritinib Drug Combo Application
Spanish stocks - Factors to watch on July 28